ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Home<List for "Pradaxa 150 mg" (12)Sort according to Concentration, Size and Price
     ProductPackage SizeEFPCPSBDCCompositionRegistr. HolderCategory    
Dabigatran Etexilate (B01AE07) 12 products WHO-DDD DrugBank.ca 
  IPCI Dabigatran Sandoz 110 mg6040.9760.9510 %Kapseln: Dabigatranum Etexilatum 110 mgSandoz
Pharmaceuticals AG
B / SL / SGGtell a friend
  IPCI Dabigatran Sandoz 110 mg180122.90150.1010 %Kapseln: Dabigatranum Etexilatum 110 mgSandoz
Pharmaceuticals AG
B / SL / SGGtell a friend
  IP  Dabigatran Sandoz 150 mg6040.9760.9510 %Kapseln: Dabigatranum Etexilatum 150 mgSandoz
Pharmaceuticals AG
B / SL / SGGtell a friend
  IP  Dabigatran Sandoz 150 mg180122.90150.1010 %Kapseln: Dabigatranum Etexilatum 150 mgSandoz
Pharmaceuticals AG
B / SL / SGGtell a friend
  IPCI Dabigatran Spirig HC 110 mg6040.9760.9510 %Kapseln: Dabigatranum Etexilatum 110 mgSpirig HealthCare AG● B / SL / SGGtell a friend
  IPCI Dabigatran Spirig HC 110 mg180122.90150.1010 %Kapseln: Dabigatranum Etexilatum 110 mgSpirig HealthCare AG● B / SL / SGGtell a friend
  IP  Dabigatran Spirig HC 150 mg6040.9760.9510 %Kapseln: Dabigatranum Etexilatum 150 mgSpirig HealthCare AG● B / SL / SGGtell a friend
  IP  Dabigatran Spirig HC 150 mg180122.90150.1010 %Kapseln: Dabigatranum Etexilatum 150 mgSpirig HealthCare AG● B / SL / SGGtell a friend
  IPCI Pradaxa 110 mg6051.2171.5010 %Kapseln: Dabigatranum Etexilatum 110 mgBoehringer Ingelheim
(Schweiz) GmbH
B / SL / SOGtell a friend
  IPCI Pradaxa 110 mg3 x 60153.63181.6010 %Kapseln: Dabigatranum Etexilatum 110 mgBoehringer Ingelheim
(Schweiz) GmbH
B / SL / SOGtell a friend
  IPCI Pradaxa 150 mg6051.2171.5010 %Kapseln: Dabigatranum Etexilatum 150 mgBoehringer Ingelheim
(Schweiz) GmbH
B / SL / SOGtell a friend
  IPCI Pradaxa 150 mg3 x 60153.63181.6010 %Kapseln: Dabigatranum Etexilatum 150 mgBoehringer Ingelheim
(Schweiz) GmbH
B / SL / SOGtell a friend
 show caption
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home